Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice
Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani, Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani
Abstract
Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of β-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a β-catenin-driven transcription program that leads to endothelial-to-mesenchymal transition. TGF-β/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate β-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.
Keywords: cerebral cavernous malformation; endothelial cells; sulindac metabolites; vascular pathology; β-catenin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Source: PubMed
Kommende kliniske studier
-
Shirley Ryan AbilityLabKiwanis Neurological Research FoundationRekrutteringTBI Traumatisk hjerneskadeForente stater
-
University of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)Har ikke rekruttert ennåVenøs tromboembolisme | Bekkenkirurgi | Abdominal kreftkirurgiForente stater
-
Fundacion para la Investigacion Biomedica del Hospital...Hospital Universitario La FeRekruttering
-
Lumetry Diagnostics GmbHKarl Landsteiner Institute for Lung Research and Pneumological Oncology; Klinik FloridsdorfHar ikke rekruttert ennåLungesykdom, kronisk obstruktiv | HyperkapniØsterrike
-
Beijing Suncadia Pharmaceuticals Co., LtdRekruttering
-
IpsenHar ikke rekruttert ennå
-
Xiangya Hospital of Central South UniversityHar ikke rekruttert ennå
-
Halic UniversityHar ikke rekruttert ennåSøvnkvalitet | Diettintervensjon | Opplevd stress | HjerneteppeTyrkia (Türkiye)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHar ikke rekruttert ennåMetastatisk brystkreft | Hormonreseptor-positiv brystkreft | HER2-lav brystkreftKina
-
The 108 Military Central HospitalVietnam Military Medical University; Thanh Phuong Co., LtdHar ikke rekruttert ennåSeptisk sjokk | Akutt nyreskadeVietnam
-
University Hospital, MontpellierHar ikke rekruttert ennåHemiparese | Spastisitet | Spastisitet i øvre ekstremiteterFrankrike
-
Kasr El Aini HospitalRekrutteringIdiopatisk granulomatøs mastittEgypt